On March 10, 2010, FDA announced that its review of data requested in June 2008 from all bisphosphonate drug manufacturers did not suggest an increased risk of subtrochanteric femur fractures (bone breaks just below the hip) in those receiving oral bisphosphonates.
On March 10, 2010, FDA announced that its review of data requested in June 2008 from all bisphosphonate drug manufacturers did not suggest an increased risk of subtrochanteric femur fractures (bone breaks just below the hip) in those receiving oral bisphosphonates.
Oral bisphosphonates such as alendronate, ibandronate, and risedronate are commonly used drugs to prevent fractures due to osteoporosis. They inhibit the digestion of bone by osteoclasts and decrease bone turnover. Administration of these drugs in patients at risk for osteoporotic fractures can reduce the incidence of vertebral and hip fractures by as much as 50% over as little as 3 years.
FDA highlighted that recent case reports have raised concerns about whether oral bisphosphonates can increase the risk of this type of fracture in patients with osteoporosis due to excessive suppression of bone turnover. However more recently, Abrahamsen and colleagues reported observational register-based study data on more than 15,000 patients, showing that both those taking (n=5,187) and not taking (n=10,374) alendronate had similar risks of atypical subtrochanteric femur fractures (14% in those receiving alendronate vs 13% in the control group, P=.70), conflicting with the findings of previous case reports. Moreover, those receiving alendronate had similar hazards of developing atypical femur fractures relative to classical osteoporotic hip fractures [(HR=1.46, 95% CI, 0.91-2.35, P=.12) vs (HR=1.45, 95% CI, 1.21-1.74, P<.001), respectively]. The authors surmised that because atypical subtrochanteric femur fractures had similar epidemiology, features, and treatment response when compared with classical osteoporotic hip fractures (including patient age, gender, and trauma mechanism), they should be classified as osteoporotic fractures.
Until then, FDA is recommending that healthcare providers who wish to prescribe an oral bisphosphonate continue to follow the usage guidelines in these products' drug labels. Furthermore, they suggest providers to discuss all the known benefits and potential risks of using an oral bisphosphonates with their patients before the decision to start or alter treatment is made.
SOURCES
1. FDA. FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures. March 10, 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203891.htm. Accessed March 15, 2010.
2. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010.
3. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study. J Bone Miner Res. 2009;24(6):1095–1102.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.